New Launch18 May 2026, 08:57 am
Glenmark USA Launches Vancomycin Hydrochloride Injection USP
AI Summary
Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial. This product is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi USA, LLC. The Vancomycin Hydrochloride for Injection USP market achieved annual sales of approximately $37.9 million for the 12-month period ending March 2026, according to IQVIA data. Glenmark's launch reflects its commitment to providing quality, affordable medicines in the U.S. and strengthens its injectable portfolio.
Key Highlights
- Glenmark USA launches Vancomycin Hydrochloride for Injection USP.
- The product is bioequivalent to Fresenius Kabi's reference drug.
- Market sales for the product reached $37.9 million in the last year.
- The launch expands access to affordable medicines in the U.S.
- It also strengthens Glenmark's injectable portfolio.